Clinical Trial Update: 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update announcing recruitment for Lutetium-177 PSMA-617 in combination with liver-directed therapy for metastatic castration-resistant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: University of California, San Francisco | Conditions: Metastatic Prostate Cancer, Prostate Cancer | Phase 1 | Status: RECRUITING